Insulin resistance Alzheimer's disease: Pathophysiology and treatment

Progress in Neurotherapeutics and Neuropsychopharmacology

Volumn 3, Issue 1, 2008, Pages 85-110

  Watson, G Stennis ^a   Craft, Suzanne ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

amyloid; Apolipoprotein; Diabetes; Exercise; Glucose metabolism; Inflammation; Insulin; Memory; Mitochondria; PPAR gamma agonists

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; CYTOKINE; GLUCOSE; INSULIN; INSULIN RECEPTOR; NEUROTRANSMITTER; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; ROSIGLITAZONE;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CELL SURVIVAL; CEREBROSPINAL FLUID; CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DYSLIPIDEMIA; EXERCISE; FACILITATION; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HETEROZYGOTE; HIGH RISK PATIENT; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LONG TERM POTENTIATION; LOW DRUG DOSE; MEMORY CONSOLIDATION; MEMORY DISORDER; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION;

EID: 39449127304     PISSN: 17482321     EISSN: 1748233X     Source Type: Journal    
DOI: 10.1017/S1748232107000031     Document Type: Article

References (126)

1. Abbott, M.A., Wells, D.G., & Fallon, J.R. (1999). The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. Journal of Neurosciences, 19, 7300-7308.
2. Akiyama, H., Barger, S., Barnum, S., et al. (2000). Inflammation and Alzheimees disease. Neurobiology of Aging, 21, 383-421.
3. Andreasen, N., & Blennow, K. (2002). Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides, 23, 1205-1214.
4. Apelt, J., Mehlhorn, G., & Schliebs, R. (1999). Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. Journal of Neuroscience Research, 57, 693-705.
5. Balakrishnan, K., Verdile, G., Mehta, P.D., et al. (2005). Plasma Abeta42 correlates positively with increased body fat in healthy individuals. Journal of Alzheimers Disease, 8, 269-282.
6. Banks, W.A., Jaspan, J.B., Huang, W., & Kastin, A.J. (1997a). Transport of insulin across the blood-brain barrier: Saturability at euglycemic doses of insulin. Peptides, 18, 1423-1429.
7. Banks, W.A., Jaspan, J.B., & Kastin, A.J. (1997b). Selective, physiological transport of insulin across the blood-brain barrier: Novel demonstration by species-specific radioimmunoassays. Peptides, 18, 1257-1262.
8. Baskin, D.G., Figlewicz, D.P., Woods, S.C., Porte Jr, D., & Dorsa, D.M. (1987). Insulin in the brain. Annual Review of Physiology, 49, 335-347.
9. Baura, G.D., Foster, D.M., Porte Jr, D. et al. (1993). Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. Journal of Clinical Investigation, 92, 1824-1830.
10. Benedict, C., Hallschmid, M., Hatke, A., et al. (2004). Intranasal insulin improves memory in humans. Psychoneumendocrinology 29, 1326-1334.
11. Bernard, N., Kitabgi, P., & Rovere-Jovene, C. (2003). The Arg617-Arg618 cleavage site in the C-terminal domain of PC1 plays a major role in the processing and targeting of the enzyme within the regulated secretory pathway. Journal of Neurochemistry, 85, 1592-1603.
12. Bingham, E.M., Hopkins, D., Smith, D., et al. (2002). The role of insulin in human brain glucose metabolism: An 18fluoro-deoxyglucose positron emission tomography study. Diabetes 51, 3384-3390.
13. Blanchard, J.G., & Duncan, P.M. (1997). Effect of combinations of insulin, glucose and scopolamine on radial arm maze performance. Pharmacology, Biochemistry and Behavior, 58, 209-214.
14. Boden, G., Lebed, B., Schatz, M., Homko, C., & Lemieux, S. (2001). Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes, 50, 1612-1617.
15. Born, J., Lange, T., Kern, W., McGregor, G.P., Bickel, U., & Fehm, H.L. (2002). Sniffing neuropeptides: A transnasal approach to the human brain. Nature Neuroscience, 5, 514-516.
16. Boyd Jr, F.T., Clarke, D.W., Muther, T.F., & Raizada, M.K. (1985). Insulin receptors and insulin modulation of norepinephrine uptake in neuronal cultures from rat brain. Journal of Biological Chemistry, 260, 15880-15884.
17. Brechtel, K., Dahl, D.B., Machann, J., et al. (2001). Fast elevation of the intramyocellular lipid content in the presence of circulating free fatty acids and hyperinsulinemia: A dynamic 1H-MRS study. Magnetic Resonance Medicine, 45, 179-183.
18. Byrne, J.H. (2003). Learning and memory: Basic mechanisms. In: Squire, L.R., Bloom, F.E., McConnell, S.K., Roberts, J.L., Spitzer, N.C., & Zigmond, M.J. (eds.), Fundamental Neuroscience (2nd ed.). San Diego, CA: Academic Press, pp. 12-76-1298.
19. Cacquevel, M., Lebeurrier, N., Cheenne, S., & Vivien, D. (2004). Cytokines in neuroinflammation and Alzheimer's disease. Current Drug Targets, 5, 529-534.
20. Carro, E., Trejo, J.L., Gomez-Isla, T., LeRoith, D., & Torres-Aleman, I. (2002). Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nature Medicine, 8, 1390-1397.
21. Combs, C.K., Johnson, D.E., Karlo, J.C., Cannady, S.B., & Landreth, G.E. (2000). Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. Journal of Neuroscience, 20, 558-567.
22. Craft, S., & Watson, G.S. (2004). Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurology, 3, 169-178.
23. Craft, S., Newcomer, J., Kanne, S., et al. (1996) Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiology of Aging, 17, 123-130.
24. Craft, S., Peskind, E., Schwartz, M.W., Schellenberg, G.D., Raskind, M., & Porte Jr, D. (1998). Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology, 50, 164-168.
25. Craft, S., Asthana, S., Newcomer, J.W., et al. (1999a). Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. The Archives of General Psychiatry, 56, 1135-1140.
26. Craft, S., Asthana, S., Schellenberg, G., et al. (1999b). Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology, 70, 146-152.
27. Craft, S., Asthana, S., Cook, D.G., et al. (2003). Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology, 28, 809-822.
28. Cuzzocrea, S., Pisano, B., Dugo, L., et al. (2004). Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. European Journal of Pharmacology, 483, 79-93.
29. Dandona, P. (2002). Endothelium, inflammation, and diabetes. Current Diabetes Reports, 2, 311-315.
30. de la Monte, S.M., & Wands, J.R. (2005). Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer's disease. Journal of Alheimers Disease, 7, 45-61.
31. de la Monte, S.M., Tong, M., Lester-Coll, N., Plater Jr, M., & Wands, J.R. (2006). Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. Journal of Alheimers Disease, 10, 89-109.
32. de Rivera, C., Shukitt-Hale, B., Joseph, J,A., & Mendelson, J.R. (2006). The effects of antioxidants in the senescent auditory cortex. Neurobiology of Aging, 27, 1035-1044.
33. Dello Russo, C., Gavrilyuk, V., Weinberg, G., et al. (2003). Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. Journal of Biological Chemistry, 278, 5828-5836.
34. Di Luca, M., Ruts, L., Gardoni, F., Cattabeni, F., Biessels, G.J., & Gispin, W.H. (1999). NMDA receptor subunits are modified transcriptionally and post-translationally in the brain of streptozotocin-diabetic rats. Diabetologia, 42, 693-701.
35. Diab, A., Deng, C., Smith, J.D., et al. (2002). Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. Journal of Immunology, 168, 2508-2515.
36. Doyle, P., Cusin, I., Rohner-Jeanrenaud, F., & Jeanrenaud, B. (1995). Four-day hyperinsulinemia in euglycemic conditions alters local cerebral glucose utilization in specific brain nuclei of freely moving rats. Brain Research, 684, 47-55.
37. Feinstein, D.L., Galea, E., Gavrilyuk, V., et al. (2002). Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Annals of Neurology, 51, 694-702.
38. Feinstein, D.L., Spagnolo, A., Akar, C., et al. (2005). Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochemical Pharmacology, 70, 177-188.
39. Ferre, P. (2004). The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes, 53(Suppl. 1), S43-S50.
40. Figlewicz, D.P., Bentson, K., & Ocrant, I. (1993a). The effect of insulin on norepinephrine uptake by PC 12 cells. Brain Research Bulletin, 32, 425-431.
41. Figlewicz, D.P., Szot, P., Israel, P.A., Payne, C., & Dorsa, D.M. (1993b). Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Research, 602, 161-164.
42. Fishel, M.A., Watson, G.S., Montine, T.J., et al. (2005). Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Archives of Neurology, 62, 1539-1544.
43. Frolich, L., Blum-Degen, D., Bernstein, H.G., et al. (1998). Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. Journal of Neural Transmission, 105, 423-438.
44. Frolich, L., Blum-Degen, D., Riederer, P., & Hoyer, S. (1999). A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Annals of the New York Academic Sciences, 893, 290-293.
45. Gasparini, L., Gouras, G.K., Wang, R., et al. (2001). Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. Journal of Neuroscience, 21, 2561-2570.
46. Gordon, E.S. (1968). Efficiency of energy metabolism in obesity. American Journal of Clinical Nutrition, 21, 1480-1485.
47. Gurnell, M. (2003). PPARgamma and metabolism: Insights from the study of human genetic variants. Clinical Endocrinology (Oxf), 59, 267-277.
48. Gustafson, D., Rothenberg, E., Blennow, K., Steen, B., & Skoog, I. (2003). An 18-year follow-up of overweight and risk of Alzheimer disease. Archives of Internal Medicine, 163, 1524-1528.
49. Hak, A.E., Pols, H.A., Stehouwer, C.D., et al. (2001). Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: The Rotterdam study. Journal of Clinical Endocrinology and Metabolism, 86, 4398-4405.
50. Hallschmid, M., Benedict, C., Schultes, B., Fehm, H.L., Born, J., & Kern, W. (2004). Intranasal insulin reduces body fat in men but not in women. Diabetes, 53, 3024-3029.
51. Harris, M.I., Flegal, K.M., Cowie, C.C., et al. (1998). Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care, 21, 518-524.
52. Havrankova, J., Roth, J., & Brownstein, M. (1978a). Insulin receptors are widely distributed in the central nervous system of the rat. Nature, 272, 827-829.
53. Havrankova, J., Schmechel, D.; Roth, J., & Brownstein, M. (1978b). Identification of insulin in rat brain. Proceedings of the National Academy of Sciences of the United States of America, 75, 5737-5741.
54. Heneka, M.T., Klockgether, T., & Feinstein, D.L. (2000). Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. Journal of Neuroscience, 20, 6862-6867.
55. Heneka, M.T., Galea, E., Gavriluyk, V., et al. (2002). Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: Implications for Alzheimer's disease. Journal of Neuroscience, 22, 2434-2442.
56. Ho, L., Qin, W., Pompl, P.N., et al. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB Journal, 18, 902-904.
57. Hoyer, S., & Lannert, H. (1999). Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats. Annals of the New York Academic Sciences, 893, 301-303.
58. Hull, M., Strauss, S., Berger, M., Volk, B., & Bauer, J. (1996). The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behavioral Brain Research, 78, 37-41.
59. Kaiyala, K.J., Prigeon, R.L., Kahn, S.E., Woods, S.C., & Schwartz, M.W. (2000). Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes, 49, 1525-1533.
60. Kern, W., Born, J., Schreiber, H., & Fehm, H.L. (1999). Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes, 48, 557-563.
61. Kim, Y.P., Kim, H., Shin, M.S., et al. (2004). Age-dependence of the effect of treadmill exercise on cell proliferation in the dentate gyrus of rats. Neuroscience Letters, 355, 152-154.
62. Kitamura, Y., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P.J., & Taniguchi, T. (1999a). Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neuroscience Letters, 262, 129-132.
63. Kitamura, Y., Shimohama, S., Koike, H., et al. (1999b). Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochemical and Biophysical Research Communications, 254, 582-586.
64. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346, 393-403.
65. Kopf, S.R., & Baratti, C.M. (1996). Effects of post-training administration of glucose on retention of a habituation response in mice: Participation of a central cholinergic mechanism. Neurobiology of Learning and Memory, 65, 253-260.
66. Krogh-Madsen, R., Plomgaard, P., Keller, P., Keller, C., & Pedersen, B.K. (2004). Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue. American Journal of Physiology, Endocrinology and Metabolism, 286, E234-E238.
67. Kulstad, JJ., Green, P.S., Cook, D.G., et al. (2006). Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology, 66, 1506-1510.
68. Kuusisto, J., Koivisto, K., Mykkanen, L., et al. (1997). Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. British Medical Journal, 315, 1045-1049.
69. Landreth, G.E., & Heneka, M.T. (2001). Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiology of Aging, 22, 937-944.
70. Larson, E.B., Wang, L., Bowen, J.D., et al. (2006). Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Annals of Internal Medicine, 144, 73-81.
71. Leibson, C.L, Rocca, W.A., & Hanson, V.A., et al. (1997). The risk of dementia-among persons with diabetes mellitus: A population-based cohort study. Annals of the New York Academy of Sciences, 826, 422-427.
72. Lester-Coll, N., Rivera, E.J., Soscia, S.J., Doiron, K., Wands, J.R., & de la Monte, S.M. (2006). Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. Journal of Alzheimers Disesae, 9, 13-33.
73. Luchsinger, J.A., Tang, M.X., Shea, S., & Mayeux, R. (2004). Hyperinsulinemia and risk of Alzheimer disease. Neurology, 63, 1187-1192.
74. Malinowski, J.M., & Bolesta, S. (2000). Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review. Clinical Therapeutics, 22, 1151-1168; discussion 1149-1150.
75. Marfaing, P., Penicaud, L., Broer, Y., Mraovitch, S., Calando, Y., & Picon, L. (1990). Effects of hyperinsulinemia on local cerebral insulin binding and glucose utilization in normoglycemic awake rats. Neuroscience Letters, 115, 279-285.
76. Marfella, R., D'Amico, M., Esposito, K., et al. (2006). The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: Effects of rosiglitazone treatment. Diabetes 55, 622-632.
77. Matsuoka, Y., Saito, M., LaFrancois, J., et al. (2003). Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. Journal of Neuroscience, 23, 29-33.
78. Mayeux, R., Honig, L.S., Tang, M.X., et al. (2003). Plasma A[beta]40 and A[beta] 42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology, 61, 1185-1190.
79. Meneilly, G.S., Cheung, E., Tessier, D., Yakura, C., & Tuokko, H. (1993). The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. Journal of Gerontology, 48, M117-M121.
80. Messier, C. (2003). Diabetes, Alzheimer's disease and apolipoprotein genotype. Experimental Gerontology, 38, 941-946.
81. MMWR Report (2003). Prevalence of diabetes and impaired fasting glucose in adults - United States, 1999-2000. Morbidity Mortality Weekly Report, 52, 833-837.
82. Molteni, R., Wu, A., Vaynaman, S., Ying, Z., Barnard, R.J., & Gomez-Pinill, F. (2004). Exercise reverses the harmful effects of consumption of a high-fat diet on synaptic and behavioral plasticity associated to the action of brain-derived neurotrophic factor. Neuroscience, 123, 429-440.
83. 2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Archives of Pathology and Laboratory Medicine, 125, 510-512.
84. Moreno, S., Farioli-Vecchioli, S., & Ceru, M.P. (2004). Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience, 123, 131-145.
85. Morgan, D. (2005). Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegenerative Diseases, 2, 261-266.
86. Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A., & Breteler, M.M. (1999). Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 53, 1937-1942.
87. Park, C.R., Seeley, R.J., Craft, S., & Woods, S.C. (2000). Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiology & Behavior, 68, 509-514.
88. Pella, R., Rodriguez, B.L., & Launer, L.J. (2002). Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes, 51, 1256-1262.
89. Pershadsingh, H.A., Heneka, M.T., Saini, R., Amin, N.M., Broeske, D.J., & Feinstein, D.L. (2004). Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. Journal of Neuroinflammation, 1, 3.
90. Pickup, J.C., Mattock, M.B., Chusney, G.D., & Burt, D. (1997). NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 40, 1286-1292.
91. Qiu, W.Q., Walsh, D.M., Ye, Z., et al. (1998). Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. Journal of Biological Chemistry, 273, 32730-32738.
92. Ragozzino, M.E., Arankowsky-Sandoval, G., & Gold, P.E. (1994). Glucose attenuates the effect of combined muscarinic-nicotinic receptor blockade on spontaneous alternation. European Journal of Pharmacology 256, 31-36.
93. Ramlo-Halsted, B.A., & Edelman, S.V. (1999). The natural history of type 2 diabetes. Implications for clinical practice. Primary Care 26, 771-789.
94. Razay, G., & Wilcock, G.K. (1994). Hyperinsulinaemia and Alzheimer's disease. Age and Ageing, 23, 396-399.
95. Reagan, L.P., Gorovits, N., Hoskin, E.K., et al. (2001). Localization and regulation of GLUTx1 glucose transporter in the hippocampus of streptozotocin diabetic rats. Proceedings of the National Academy of Sciences of United States America, 98, 2820-2825.
96. Reaven, G.M., Chang, H., & Hoffman, B.B. (1988). Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes, 37, 28-32.
97. Reger, M.A., Watson, G.S., Frey 2nd, W.H., et al. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiology of Aging, 27, 451-458.
98. Risner, M.E., Saunders, A.M., Altman, J.F., et al. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics Journal, 6, 246-254.
99. Rivera, E.J., Goldin, A., Fulmer, N., Tavares, R., Wands, J.R., & de la Monte, S.M. (2005). Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. Journal of Alzheimer's Disease, 8, 247-268.
100. Rosler, N., Wichart, L., & Jellinger, K.A. (2001). Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients. Acta Neurologica Scandinavica, 103, 126-130.
101. Ruan, H., & Lodish, H.F. (2003). Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-alpha. Cytokine & Growth Factor Reviews, 14, 447-455.
102. Santomauro, A.T., Boden, G., Silva, M.E., et al. (1999). Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes, 48, 1836-1841.
103. Sastre, M., Dewachter, I., Landreth, G.E., et al. (2003). Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. Journal of Neuroscience, 23, 9796-9804.
104. Schubert, M., Gautam, D., Surjo, D., et al. (2004). Role for neuronal insulin resistance in neurodegenerative diseases. Proceedings of the National Academy of Sciences of the United States of America, 101, 3100-3105.
105. Schulingkamp, R.J., Pagano, T.C., Hung, D., & Raffa, R.B. (2000). Insulin receptors and insulin action in the brain: Review and clinical implications. Neuroscience and Biobehavioral Reviews, 24, 855-872.
106. Schwartz, M.W., Figlewicz, D.F., Kahn, S.E., Baskin, D.G., Greenwood, M.R., & Porte Jr. D. (1990). Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 11, 467-472.
107. Sidhu, J.S., Cowan, D., & Kaski,J.C. (2003). The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. Journal of the American College of Cardiology, 42, 1757-1763.
108. Skeberdis, V.A., Lan, J., Zheng, X., Zukin, R.S., & Bennett, M.V. (2001). Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell-surface by exocytosis. Proceedings of the National Academy of Sciences of United States of America, 98, 3561-3566.
109. Soop, M., Duxbury, H., Agwunobi, A.O., et al. (2002). Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. American Journal of Physiology, Endocrinology and Metabolism, 282, E1276-E1285.
110. Steen, E., Terry, B.M., Rivera, E.J., et al. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? Journal of Alzheimers Disease, 7, 63-80.
111. Strachan, M.W., Deary, I.J., Ewing, F.M., & Frier, B.M. (1997). Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20, 438-445.
112. Thorne, R.G., Pronk, G.J., Padmanabhan, V., & Frey 2nd, W.H. (2004), Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 127, 481-496.
113. Trejo, J.L., Carro, E., & Torres-Aleman, I. (2001). Circulating insulin-like grovith factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. Journal of Neuroscience, 21, 1628-1634.
114. Tuomilehto, J., Lindstrom, J., Eriksson, J.G., et al. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine, 344, 1343-1350.
115. Unger, J.W., Livingston, J.N., & Moss, A.M. (1991). Insulin receptors in the central nervous system: Localization, signalling mechanisms and functional aspects. Progress in Neurobiology, 36, 343-362.
116. Uryu, S., Harada, J., Hisamoto, M., & Oda, T. (2002). Troglitazone inhibits both postglutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Research, 924, 229-236.
117. van der Heide, L.P., Kamal, A., Artola, A., Gispen, W.H., & Ramakers, G.M. (2005). Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-D-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner. Journal of Neurochemistry, 94, 1158-1166.
118. Vanhanen, M., Koivisto, K., Kuusisto, J., et al. (1998). Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care, 21, 398-402.
119. Wang, J., Ho, L., Qinq W., et al. (2005). Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB Journal, 19, 659-661.
120. Watson, G.S., & Craft, S. (2003).The role of insulin resistance in the pathogenesis of Alzheimer's disease: Implications for treatment. CNS Drugs, 17, 27-45.
121. Watson, G.S., & Craft, S. (2004). Modulation of memory by insulin and glucose: Neuropsychological observations-in Alzheimer's disease. European Journal of Pharmacology, 490, 97-113.
122. Watson, G.S., Peskind, E.R., Asthana, S., et al. (2003). Insulin increases CSF Abeta42 levels in normal older adults. Neurology, 60, 1899-1903.
123. Watson, G.S., Cholerton, B.A., Reger, M.A., et al. (2005). Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. American Journal of Geriatric Psychiatry, 13, 950-958.
124. Watson, G.S., Bernhardt, T., Reger, M.A., et al. (2006a). Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiology of Aging, 27, 38-41.
125. Watson, G.S., Reger, M.A., Baker, L.D., et al. (2006b). Effects of exercise and nutrition on memory in Japanese-Americans with impaired glucose tolerance. Diabetes Care, 29, 135-136.
126. Zhao, W., Chen, H., Xu, H., et al. (1999). Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. Journal of Biological Chemistry, 274, 34893-34902.